Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Colorcon
Medtronic
Citi
Argus Health
AstraZeneca
Chubb
Harvard Business School
McKesson
Daiichi Sankyo

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,114,319

« Back to Dashboard

Which drugs does patent 6,114,319 protect, and when does it expire?


Patent 6,114,319 protects DUREZOL and is included in one NDA. There has been one Paragraph IV challenge on Durezol.

Protection for DUREZOL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has six patent family members in five countries.

Summary for Patent: 6,114,319

Title: Compositions containing difluprednate
Abstract:The present invention relates to a liquid composition comprising difluprednate, oil, water and an emulsifier. The composition of the present invention has superior antiinflammatory action and antiallergic action. The composition of the present invention shows superior transfer to a lesion and uniform drug distribution upon administration, as compared to conventional preparations containing difluprednate, so that it shows sufficient efficacy in a smaller dose. The inventive composition is associated with extremely less uncomfortable feeling and foreign sensation upon administration, as compared to conventional preparations containing difluprednate, and it can be administered easily to local sites of eye, nose, ear and the like.
Inventor(s): Kimura; Masako (Kakogawa, JP), Yasueda; Shin-ichi (Kobe, JP), Yamaguchi; Masazumi (Kobe, JP), Inada; Katsuhiro (Kobe, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (JP) Mitsubishi Chemical Corporation (JP)
Application Number:09/076,124
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
DUREZOL
difluprednate
EMULSION;OPHTHALMIC022212-001Jun 23, 2008RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,114,319

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-124415May 14, 1997

International Patent Family for Patent: 6,114,319

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0878197► Subscribe
Germany69807281► Subscribe
China1200926► Subscribe
Canada2237503► Subscribe
JapanH1129483► Subscribe
Japan3410364► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Colorcon
Deloitte
Covington
Moodys
Accenture
Harvard Business School
Medtronic
McKinsey
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot